UK markets closed

Supernus Pharmaceuticals, Inc. (0LB2.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
29.46-3.04 (-9.35%)
At close: 05:59PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.99
52-week change 3-3.52%
S&P500 52-week change 325.01%
52-week high 338.65
52-week low 30.00
50-day moving average 327.93
200-day moving average 329.84

Share statistics

Avg vol (3-month) 383
Avg vol (10-day) 390
Shares outstanding 552.26M
Implied shares outstanding 6N/A
Float 847.71M
% held by insiders 15.12%
% held by institutions 1108.15%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.22%
Operating margin (ttm)11.56%

Management effectiveness

Return on assets (ttm)0.56%
Return on equity (ttm)0.15%

Income statement

Revenue (ttm)607.52M
Revenue per share (ttm)11.14
Quarterly revenue growth (yoy)-1.80%
Gross profit (ttm)N/A
EBITDA 98.26M
Net income avi to common (ttm)1.32M
Diluted EPS (ttm)1.31
Quarterly earnings growth (yoy)-95.40%

Balance sheet

Total cash (mrq)254.87M
Total cash per share (mrq)4.66
Total debt (mrq)41.53M
Total debt/equity (mrq)4.51%
Current ratio (mrq)1.70
Book value per share (mrq)16.84

Cash flow statement

Operating cash flow (ttm)111.08M
Levered free cash flow (ttm)161.71M